Home › Scleroderma › Connecticut › New Haven
Scleroderma clinical trials in New Haven, CT
4 studies for Scleroderma are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
- Yale University, New Haven
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
RecruitingObservational study
- Yale Scleroderma Program, New Haven
Rheumatology Patient Registry and Biorepository
RecruitingObservational studyHealthy volunteers welcome
- Yale New Haven Hospital, New Haven
About Scleroderma
Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.
More about Scleroderma on MedlinePlus
Scleroderma trials in other cities
- New York City, NY11 studies
- Ann Arbor, MI10 studies
- Chicago, IL10 studies
- Houston, TX9 studies
- Boston, MA7 studies
- Durham, NC7 studies
- Los Angeles, CA7 studies
- New Orleans, LA6 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- Dallas, TX5 studies
- Pittsburgh, PA5 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer41 studies
- Breast Cancer37 studies
- Cancer (all types)33 studies
- Metastatic Cancer23 studies
- Lung Cancer22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Ovarian Cancer21 studies
- Colorectal Cancer20 studies
- Prostate Cancer20 studies
- Opioid Overdose18 studies
- Alcohol Use Disorder (AUD)17 studies
- Acute Myeloid Leukemia17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.